NCT06507839

Study to Assess the Safety, Tolerability, Pharmacokinetic of Thrv-1268

A First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study To Assess the Safety, Tolerability, Pharmacokinetics, and Food Effect of Thrv-1268 in Healthy Adult Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 56 (actual)
• Sponsor: Thryv Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This is a single-center, randomized, double-blind, placebo-controlled study to be conducted in 2 parts: single ascending dose (SAD) incorporating a food effect arm and multiple ascending dose (MAD). Potential participants for each part will undergo screening procedures within 28 days of enrollment.

Conditions

• Atrial Fibrillation

Interventions

Type	Name	Description
DRUG	THRV-1268	THRV-1268 a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor
OTHER	Placebo	Matching placebo

Timeline

• Start date: 2024-05-15
• Primary completion: 2024-11-01
• Completion: 2024-11-01
• First posted: 2024-07-18
• Last updated: 2025-05-13

Locations

1 site across 1 country: Canada